Overview
ZYLOXTB (2190)
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s R...
- Open
- 18.190
- High
- 18.190
- Low
- 17.800
- Prev. Close
- 18.280
- Volume
- 502.02K
- Turnover
- 9.03M
- Avg Price
- 17.997
- Bid/Ask Ratio
- -64.71%
- Amplitude
- 2.13%
- 52wk High
- 27.748
- Volume Ratio
- 2.03
- Turnover Ratio
- 0.16%
- 52wk Low
- 17.100
- HK Mkt Cap
- 5.85B
- Market CapHKD
- 5.99B
- P/ETTM
- 17.07
- P/EDynamic
- 14.32
- P/EStatic
- --
- EPSTTM
- 1.06
- EPSDynamic
- 1.27
- EPSStatic
- --
- BVPS
- 10.39
- P/B
- 1.75
- HK Shares
- 322.06M
- Dividend YieldTTM
- 1.40%
- DividendTTM
- 0.255
- Shares
- 329.84M
- Min lot size
- 500
- Currency
- HKD
ZYLOXTB Analyst Rating
View moreForecast & Rating
Nov 9, 2026- Strong buy60.00%
- Buy40.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 13
Zylox-Tonbridge closed up about 3.5% at HK$18.97 against the prior close of HK$18.33, driven by its joint HK$1.48 billion move with GL Capital to buy a 16.7% LifeTech stake, of which the company funds HK$889 million while pursuing a potential merger and a concurrent H-share placement. The session traced a dip-and-recover shape: it opened at HK$18.85, slid to HK$17.70 by 13:27 BJ time, then climbed back through the afternoon to settle at HK$18.97. Fundamentals underpin the move, with Q2 2026 revenue of HK$365.0 million up 38.2% YoY, net profit of HK$104.9 million up 58.0%, operating income up 134.4%, a 28.75% net margin and EPS of HK$0.3292 up 62.4%. Still, the shares sit below the MA20 of HK$19.27 and MA60 of HK$20.48, down 16.8% year-to-date and 32.3% below the 52-week high of HK$28, at 17.8x PE and HK$6.26 billion market cap, while placement dilution and integration risk remain open.
- Nov, 12
Zylox-Tonbridge fell 2.47% to HK$18.20 in a spike-and-fade session, as profit-taking followed a 12% one-day jump on the proposed HK$1.48 billion purchase of a 16.7% stake in LifeTech Scientific alongside an H-share placement; the stock opened at HK$19.11 and slid to an intraday low of HK$18.14 at 13:21 BJ before closing near the day's low. Fundamentals still underpin the story, with Q2 2026 revenue up 38.23% year on year to HK$365.0 million, net profit up 58.04% to HK$104.9 million, operating income up 134.4% and first-half net profit up 47.8% to RMB179.1 million on a 28.75% net margin. Yet the shares trade below the MA20 of HK$19.38 and MA60 of HK$20.50, down 20.18% year to date, 35% below the 52-week high of HK$28 and only 6.43% above the 52-week low of HK$17.1, at 17.1x PE with turnover of just HK$12.98 million and a 0.22% turnover rate, while placement dilution concerns keep rebounds in check.
- Nov, 9
Shares opened up 8.3% at HK$21.00 but unwound through the session to close at the intraday low of HK$18.96, down 2.2%, as the plan to buy a 16.7% stake in LifeTech Scientific alongside GL Capital for HK$1.48 billion, paired with a concurrent H-share placement at roughly a 13.5% premium raising about HK$864 million net, put dilution and cash-out concerns ahead of platform consolidation; the same deal had lifted the stock more than 12% in the prior session. Fundamentals remain firm: Q2 2026 revenue of HK$365.0 million rose 38.2% year on year, net profit HK$104.9 million gained 58.0%, EPS HK$0.3292 climbed 62.4% and operating income rose 134.4%, at a PE of 17.8x and PB of 1.83x. The close sits below the MA20 of HK$19.71 and MA60 of HK$20.56, down 16.8% year to date, 32.3% below the 52-week high of HK$28.00 yet 10.9% above the HK$17.10 low. Though repeated buybacks of about 53,000 shares for roughly HK$1.13-1.16 million per day since late September may cushion the downside near lows.
- Oct, 22
ZYLOXTB opened at HK$21.02 and slid in a one-way decline, touching and closing at HK$19.40 in the afternoon session, roughly 5.4% below the prior close of HK$20.50, on thin turnover of 274,936 shares worth HK$5.47 million. The move contrasts with Q2 2026 results: revenue of HK$365.0 million, up 38.23% year on year, net profit of HK$104.9 million, up 58.04%, operating income up 134.4%, and EPS of HK$0.3292, up 62.39%. The price sits below both the MA20 of HK$20.958 and the MA60 of HK$20.554, down 13.2% year to date and 29.32% below the 52-week high of HK$28.00. Since mid-September the company has bought back about 53,000 to 55,500 shares almost daily, spending roughly HK$1.13 to 1.16 million each time, while AIH Capital added 118,000 shares near HK$20.50; though the light volume suggests such repurchases gave limited near-term price support.
- Oct, 13
Supported by continued buybacks and interim results, the stock staged a low-open, dip-and-recover session, closing at HK$21.06 versus a prior close of HK$20.34, up about 3.5%, after an intraday low of HK$20.12 shortly after the open and a high of HK$21.14 at 13:31 BJ, on turnover of roughly HK$22.3 million. The company has repeatedly repurchased and cancelled shares in the HK$20.82-21.38 and HK$21.78-22.2 ranges, and most brokers rate it buy. Fundamentals echo the move: Q2 2026 EPS of HK$0.3292 rose 62.4% yoy, revenue of HK$365 million gained 38.2%, operating income climbed 134.4%, and first-half net profit rose 47.8% to RMB179.1 million, with GF Securities keeping a Buy rating. The price remains about 24.8% below its 52-week high of HK$28 and down 7.6% year-to-date, though it now stands above its MA20 of HK$21.05 and MA60 of HK$20.45. At 19.8x PE, however, further re-rating still hinges on earnings delivery.
News
Tip Ranks · Zylox-Tonbridge Changes Joint Company Secretary and Representatives
Weekly Review · Weekly Recap | ZYLOXTB -3.59%, most brokers rate it buy
Market Movers · Zylox-Tonbridge surges 12% on Lifetech stake deal and share placement
PR Newswire · Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform
PUBT · Zylox-Tonbridge, GL Capital Agree to Buy 16.7% Stake in LifeTech for HKD 1.48 Billion
